文献速递临床试验与 GCP

高危低级别胶质瘤术后放疗对比放疗联合替莫唑胺:随机对照临床试验研究方案

Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2019-11-21

本研究为两组随机对照试验,拟纳入250例高危WHO 2级低级别胶质瘤术后患者,1:1随机接受单纯放疗或放疗联合替莫唑胺化疗,主要终点为无进展生存期,采用意向性分析,旨在评估联合替莫唑胺能否改善无进展生存期和总生存期。

要点

  • 纳入标准为年龄≥40岁不限切除程度,或年龄<40岁伴次全切除或活检的WHO 2级低级别胶质瘤术后患者。
  • 拟纳入250例,1:1随机分配至单纯放疗组或放疗联合替莫唑胺组。
  • 主要终点为无进展生存期,采用意向性分析;次要终点包括总生存期、不良事件和认知功能。

核心结论

  • 本试验旨在确认放疗联合替莫唑胺能否改善高危低级别胶质瘤患者的无进展生存期和总生存期。
  • 不同组织学类型和分子亚型将被检查,并进行相应的亚组分析。
  • 研究数据可为中国高危低级别胶质瘤患者的术后辅助治疗提供证据。

研究设计与样本

  • 两组随机对照试验,拟纳入250例WHO 2级低级别胶质瘤术后患者,1:1随机分配至单纯放疗组或放疗联合替莫唑胺组。
  • 纳入标准为年龄40岁及以上不限切除程度,或年龄小于40岁伴次全切除或活检。
  • 所有受试者接受相同放疗;联合组接受辅助替莫唑胺化疗,伴或不伴同步放化疗。
  • 主要终点无进展生存期采用意向性分析;次要终点包括总生存期、不良事件和认知功能。
  • 试验注册于中国临床试验注册中心,注册号ChiCTR1800015199,注册日期2018年3月13日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It has been reported that radiation therapy (RT) followed by procarbazine, lomustine, and vincristine (PCV) chemotherapy could improve progression-free survival (PFS) and overall survival (OS) in patients with high-risk World Health Organization (WHO) grade 2 gliomas after surgery. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide (TMZ) to treat these patients, although large-scale prospective studies are lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and OS in high-risk patients with low-grade gliomas (LGGs). METHODS/DESIGN: This is a two-group, randomized controlled trial (RCT) enrolling patients who have LGGs (WHO grade 2) and are aged 40 years or older without regard to the extent of resection or are aged younger than 40 years old with subtotal resection or biopsy. An estimated 250 patients will be enrolled. Eligible participants will be randomly assigned to receive RT alone or RT plus TMZ chemotherapy in a 1:1 ratio. The same RT will be given to all eligible participants regardless of whether they are randomly assigned to the RT group or the chemoradiotherapy (CRT) group. While in the CRT group, patients will receive adjuvant TMZ with or without concurrent radiochemotherapy. The primary outcome of this trial is PFS, and it will be analyzed by the intention-to-treat approach. Secondary outcomes include OS, adverse events, and cognitive function. DISCUSSION: The objective of our research is to assess the effect of radiotherapy coupled with TMZ in high-risk patients with LGGs after surgery, compared with RT alone. Different histological types and molecular subtypes will be examined, and a corresponding subgroup analysis will be conducted. Our data can provide evidence for postoperative adjuvant therapy in patients with high-risk LGGs in China. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800015199. Registered on 13 March 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang J, Wang Y, He Y, et al. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial. Trials. 2019. PMID: 31752981. doi:10.1186/s13063-019-3741-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。